Live Breaking News & Updates on Katja Weisel|Page 1

Stay updated with breaking news from Katja weisel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Despite evidence of durability, belantamab mafodotin misses endpoint for multiple myeloma

CHICAGO — Belantamab mafodotin monotherapy did not significantly extend PFS compared with the combination of pomalidomide and dexamethasone among adults with relapsed or refractory multiple myeloma, phase 3 study results showed. However, data from the randomized trial presented at ASCO Annual Meeting suggest that single-agent treatment with belantamab mafodotin (Blenrep, GSK) may have ....

Nordrhein Westfalen , United States , Joshua Richter , Mindy Valcarcel , Katja Weisel , Bydrew Amorosi , University Medical Center Hamburg , Bristol Myers Squibb , University Medical Center Hamburg Eppendorf ,

The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study

/PRNewswire/ The European Myeloma Network (EMN), an international collaborative network of expertise centers for multiple myeloma in Europe and Australia,. ....

United States , United Kingdom , Kyongsang Bukto , South Korea , Katja Weisel , Mario Boccadoro , Reshma Rangwala , Pieter Sonneveld , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , National Cancer Institute , Drug Administration , Exchange Commission , Karyopharm Selective Inhibitor Of Nuclear Export , Information Department , University Cancer Center , American Cancer Society , European Myeloma Network , All Oral Regimen , Low Dose Dexamethasone , Refractory Multiple Myeloma , Karyopharm Therapeutics , Chief Medical Officer , Multiple Myeloma , Professor Katja Weisel , Deputy Director ,

World Cancer Day: Groundbreaking new treatments approved in Israel

World Cancer Day is on February 4 and is commemorated in over 116 countries globally. ....

Nordrhein Westfalen , France General , Katja Weisel , Belantamab Mafodotin , Union For International Cancer , European Commission , University Medical Center Hamburg , Assuta Ashdod University Hospital , World Cancer Day , World Summit Against Cancer , New Millennium , International Cancer Control , Ashdod University Hospital , University Medical Center Hamburg Eppendorf , Cervical Cancer Awareness Week , Scare Gap ,

CAR T-cell therapy generates lasting remissions in patients with multiple myeloma

Credit: Dana-Farber Cancer Institute
In a major advance in the treatment of multiple myeloma, a CAR T-cell therapy has generated deep, sustained remissions in patients who had relapsed from several previous therapies, an international clinical trial has found.
In a study posted online today by the
New England Journal of Medicine, trial leaders report that almost 75% of the participants responded to the therapy, known as idecabtagene vicleucel (ide-cel), and one-third of them had a complete response, or disappearance of all signs of their cancer. These rates, and the duration of the responses, are significantly better than those produced by currently available therapies for patients with multiple relapses, according to investigators. ....

New York , United States , Nordrhein Westfalen , Region Flamande , Comunidad Autonoma De Cataluna , San Francisco , Dana Farber Cancer Institute , Baden Wuberg , United Kingdom , Institut Catala , Liping Huang , Triasi Pujol , Alessandro Rambaldi , Donna Reece , Nikhil Munshi , Jamien Connarn , Monica Massaro , David Siegel , Shari Kaiser , Nina Shah , Deepu Madduri , Michele Cavo , Hermann Einsele , Territoriale Papa Giovanni , Philippe Moreau , Yi Lin ,